A study on the effects of culture supernatant of human somatic stem cells on liver cirrhosis

A study on the effects of culture supernatant of human somatic stem cells on liver cirrhosis - The effects of culture supernatant of human somatic stem cells on liver cirrhosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015557

Enrollment

Registered

2014-10-29

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

Intravenous or intranasal administration of culture supernatant of human somatic stem cells

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with liver cirrhosis under treatment Treatment has not been changed in the previous month and it is anticipated that the treatment will not be changed in the next month Patients with T-bil less than 5mg/dl and serum Alb less than or equal 3.5g/dl

Exclusion criteria

Exclusion criteria: Patients with malignant diseases

Design outcomes

Primary

Measure	Time frame
Safety: Adverse events and laboratory tests	—

Secondary

Measure	Time frame
Efficacy: Clinical symptoms and laboratory tests	—

Countries

Japan

Contacts

Public ContactHiroshi Terunuma

Tokyo Clinic Internal Medicine

terunuma.h@gmail.com03-3516-7165

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026